

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the spelling of name of Receiving Party on the Cover Sheet previously recorded on Reel 003959 Frame 0651. Assignor(s) hereby confirms the correct spelling of name of the Receiving Party is OncoGenex Pharmaceuticals, Inc..

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Sonus Pharmaceuticals, Inc.		08/19/2008	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	OncoGenex Pharmaceuticals, Inc.
Street Address:	1522 - 217th Place SE, Suite 100
City:	Bothell
State/Country:	WASHINGTON
Postal Code:	98021
Entity Type:	CORPORATION: DELAWARE

PROPERTY NUMBERS Total: 1

Property Type	Number	Word Mark
Registration Number:	2824000	TOCOSOL

CORRESPONDENCE DATA

Fax Number: (206)224-0779
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 206-682-8100
 Email: susan.bermel@cojk.com
 Correspondent Name: Daiva K. Tautvydas
 Address Line 1: 1420 Fifth Avenue, Suite 2800
 Address Line 4: Seattle, WASHINGTON 98101-2347

ATTORNEY DOCKET NUMBER:	SNST-2-26996
NAME OF SUBMITTER:	Daiva K. Tautvydas
Signature:	/Daiva K. Tautvydas/

Date:

03/31/2009

Total Attachments: 4

source=Name Change to OncoGenex#page1.tif

source=Name Change to OncoGenex#page2.tif

source=Name Change to OncoGenex#page3.tif

source=OncoGenex Cover Sheet#page1.tif

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	CHANGE OF NAME		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Sonus Pharmaceuticals, Inc.		08/19/2008	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	OncoGenix Pharmaceuticals, Inc.		
Street Address:	1522 - 217th Place SE, Suite 100		
City:	Bothell		
State/Country:	WASHINGTON		
Postal Code:	98021		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	2824000	TOCOSOL	
CORRESPONDENCE DATA			
Fax Number:	(206)224-0779		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	206-682-8100		
Email:	susan.bermel@cojk.com		
Correspondent Name:	Daiva K. Tautvydas		
Address Line 1:	1420 Fifth Avenue, Suite 2800		
Address Line 4:	Seattle, WASHINGTON 98101-2347		
ATTORNEY DOCKET NUMBER:	SNST-2-26996		

Delaware

PAGE 1

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "SONUS PHARMACEUTICALS, INC.", CHANGING ITS NAME FROM "SONUS PHARMACEUTICALS, INC." TO "ONCOGENEX PHARMACEUTICALS , INC.", FILED IN THIS OFFICE ON THE TWENTIETH DAY OF AUGUST, A.D. 2008, AT 3:44 O'CLOCK P.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF AMENDMENT IS THE TWENTIETH DAY OF AUGUST, A.D. 2008, AT 4:01 O'CLOCK P.M.

2481601 8100

080903277

You may verify this certificate online
at corp.delaware.gov/authver.shtml



Harriet Smith Windsor

Harriet Smith Windsor, Secretary of State

AUTHENTICATION: 6814452

DATE: 08-26-08

TRADEMARK

REEL: 003962 FRAME: 0070

CERTIFICATE OF AMENDMENT
OF
CERTIFICATE OF INCORPORATION
OF
SONUS PHARMACEUTICALS, INC.
a Delaware Corporation

(pursuant to Section 242 of the Delaware General Corporation Law)

SONUS PHARMACEUTICALS, INC., a corporation organized and existing under and by the virtue of the Delaware General Corporation Law (the "Corporation"), through its duly authorized officers and by authority of its Board of Directors does hereby certify:

FIRST: That in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware, the Board of Directors of the Corporation duly adopted resolutions setting forth proposed amendments to the Amended and Restated Certificate of Incorporation of the Corporation, declaring said amendments to be advisable and directing that said amendments be submitted to the stockholders of the Corporation for consideration thereof. The resolutions setting forth the proposed amendments are as follows:

RESOLVED, that Article I of the Corporation's Amended and Restated Certificate be amended to read as follows:

"The name of this Corporation is OncoGenex Pharmaceuticals, Inc."

RESOLVED FURTHER, that the first two sentences of the text of Article IV of the Corporation's Amended and Restated Certificate of Incorporation be deleted and replaced with the following text:

"This Corporation is authorized to issue two classes of stock to be designated respectively, "Common Stock" and "Preferred Stock " Upon the effectiveness of this Certificate of Amendment of Certificate of Incorporation, every eighteen (18) shares of the Corporation's issued and outstanding Common Stock shall, automatically and without any action on the part of the holder thereof, be reclassified and changed into one (1) share of the Corporation's Common Stock, par value \$0.001 per share (the "Reverse Stock Split"). After giving effect to the Reverse Stock Split, the total number of shares of all classes of stock which the Corporation shall have authority to issue is 16,019,930, of which (i) 11,019,930 shares shall be designated Common Stock and shall have a par value of \$.001 per share; and (ii) 5,000,000 shares shall be designated Preferred Stock and shall have a par value of \$.001 per share."

SECOND: That thereafter, pursuant to a resolution of its Board of Directors, in accordance with Section 242 of the General Corporation Law of the State of Delaware, the Corporation's stockholders approved and authorized the foregoing Certificate of Amendment.


THIRD: That the foregoing Certificate of Amendment was duly adopted in accordance with the provisions of Section 242 of the Delaware General Corporation Law.

FOURTH: That this Certificate of Amendment shall be made effective as of 4:01 p.m. Eastern Standard Time on August 20, 2008.

IN WITNESS WHEREOF, this Corporation has caused this Certificate of Amendment to be signed by Michael A. Martino, its duly authorized President and Chief Executive Officer this 19th day of August, 2008.

SONUS PHARMACEUTICALS, INC.
a Delaware Corporation

By:



Michael A. Martino
President and Chief Executive Officer

TRADEMARK